KRAS G12C-Mutated Non-Small Cell Lung Cancer
KRAS G12C-mutated non-small cell lung cancer is a type of lung cancer that has a specific mutation in the KRAS gene, which can affect how the cancer grows and responds to treatment.
Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation
We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you over 18 years old?
- Do you have a confirmed diagnosis of non-small cell lung cancer (NSCLC) stage III or IV that cannot be cured?
- Are you currently pregnant or breastfeeding?
- Are you taking blood thinners like Warfarin, Eliquis, or Xarelto?
- Have you had major surgery in the past 4 weeks?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Odense University Hospital
Department of Oncology
Odense, Denmark
Helse Bergen HF
Pulmonary department
Bergen, Norway
Vestre Viken HF
Department of Oncology
Drammen, Norway
Sponsor: Vestre Viken HF
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.